Cargando…
Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or ag...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873680/ https://www.ncbi.nlm.nih.gov/pubmed/24300563 http://dx.doi.org/10.3390/pharmaceutics5040570 |
_version_ | 1782297137701191680 |
---|---|
author | Cavallari, Cristina Fini, Adamo Ceschel, Giancarlo |
author_facet | Cavallari, Cristina Fini, Adamo Ceschel, Giancarlo |
author_sort | Cavallari, Cristina |
collection | PubMed |
description | Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or aged (one year) samples. Drug and carriers were preliminarily selected in order to avoid problems related to the aging of the formulation, according to the solubility parameters of carriers and drug. These parameters make it possible to predict the low solubility of olanzapine in the carriers (alone or in mixtures). Systems containing only Lutrol (also in the presence of Transcutol(®)) contain the drug in the form of particles of reduced size and in a crystalline form. Gelucire(®) 44/14 apparently increases the amount of olanzapine dissolved in the solid carrier, but this is presumed to be a metastable state, probably related to the heterogeneous nature of the carrier that delays crystallization of the drug. The high hydrophilicity of the carriers proves suitable to an accelerated and quick release of the drug regardless of aging. Differences in the release profiles between Lutrol- and Gelucire-containing systems were interpreted in terms of the formation of polymer micelles by the Lutrols when in aqueous solution. |
format | Online Article Text |
id | pubmed-3873680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38736802014-01-06 Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances Cavallari, Cristina Fini, Adamo Ceschel, Giancarlo Pharmaceutics Article Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or aged (one year) samples. Drug and carriers were preliminarily selected in order to avoid problems related to the aging of the formulation, according to the solubility parameters of carriers and drug. These parameters make it possible to predict the low solubility of olanzapine in the carriers (alone or in mixtures). Systems containing only Lutrol (also in the presence of Transcutol(®)) contain the drug in the form of particles of reduced size and in a crystalline form. Gelucire(®) 44/14 apparently increases the amount of olanzapine dissolved in the solid carrier, but this is presumed to be a metastable state, probably related to the heterogeneous nature of the carrier that delays crystallization of the drug. The high hydrophilicity of the carriers proves suitable to an accelerated and quick release of the drug regardless of aging. Differences in the release profiles between Lutrol- and Gelucire-containing systems were interpreted in terms of the formation of polymer micelles by the Lutrols when in aqueous solution. MDPI 2013-10-25 /pmc/articles/PMC3873680/ /pubmed/24300563 http://dx.doi.org/10.3390/pharmaceutics5040570 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Cavallari, Cristina Fini, Adamo Ceschel, Giancarlo Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title | Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title_full | Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title_fullStr | Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title_full_unstemmed | Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title_short | Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances |
title_sort | design of olanzapine/lutrol solid dispersions of improved stability and performances |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873680/ https://www.ncbi.nlm.nih.gov/pubmed/24300563 http://dx.doi.org/10.3390/pharmaceutics5040570 |
work_keys_str_mv | AT cavallaricristina designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances AT finiadamo designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances AT ceschelgiancarlo designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances |